ENDOCRINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-02-26 ms5000000066723286 来自江苏省

审稿速度:1.0
偏重的研究方向：糖尿病
经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept

57 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-05-04 ms6000000585377014 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：甲状腺肿瘤
经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投

6 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-04-23 zhangly92 来自广东省

投稿系统里的article type没有original article，各位都是选择什么选项投稿的？

7 0

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-04-23 zhangly92 来自广东省

问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？

6 0

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-04-15 ms5000001120338885 来自重庆

请问一般多久online呀

12 0

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-04-08 ms6000000830172102 来自安徽省

请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？

16 0

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-03-10 Bandore 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：甲状腺
经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。

1 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-04-03 1234456789 来自江苏省

还没投

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-04-01 1234456789 来自江苏省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：在投中

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2189418, encodeId=64d7218941826, content=审稿速度:1.0 偏重的研究方向：糖尿病 经验分享：期刊转投，副主编和独立审稿人各一个审稿。 23.11.13 submit 23.11.15 with editor 23.11.16 under review 23.11.17 under review（审稿人接受审稿） 23.12.17 under review（第一个审稿意见） 23.12.19 under review（第二个审稿人） 24.1.19 required reviews completed（第二个审稿意见） 24.1.21 decision in process 24.1.22 major revision 24.2.2 revision submit 24.2.3 with editor 24.2.4 under review 24.2.5 required reviews completed / decision in process 24.2.6 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21888273920, createdName=ms5000000066723286, createdTime=Mon Feb 26 11:07:51 CST 2024, time=2024-02-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2201654, encodeId=57ad220165431, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺肿瘤 经验分享：2月9号投稿 3月13号返修只有一个审稿人修了2周修回去，4月初接受，责任编辑是主编，权利大，人很好，接受后会先proof，然后问你要不要交版面费。值得投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7175494638, createdName=ms6000000585377014, createdTime=Sat May 04 00:07:31 CST 2024, time=2024-05-04, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199958, encodeId=2bed2199958f3, content=投稿系统里的article type没有original article，各位都是选择什么选项投稿的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 14:59:42 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2199959, encodeId=19812199959c0, content=问下投稿时选择article type，没有originl article 这个选项，都选择的是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5282129934, createdName=zhangly92, createdTime=Tue Apr 23 15:08:20 CST 2024, time=2024-04-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2198589, encodeId=40032198589dc, content=请问一般多久online呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e7c5623450, createdName=ms5000001120338885, createdTime=Mon Apr 15 12:16:42 CST 2024, time=2024-04-15, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2197423, encodeId=d521219e4230e, content=请问Technical check后面是Peer review，Peer review已经持续一个月了，是送审了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13069193199, createdName=ms6000000830172102, createdTime=Mon Apr 08 17:37:43 CST 2024, time=2024-04-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2192398, encodeId=9726219239850, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：甲状腺 经验分享：12 月投稿，1 月返修，2 月发表。最后确认时可以选择非 oa，不用版面费，编辑人也很好，总体而言挺推荐的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/17d5b4b6ce8a46658d891ee8430d192f-qHBLJweRbHSY.jpg, createdBy=25008441399, createdName=Bandore, createdTime=Sun Mar 10 15:06:47 CST 2024, time=2024-03-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2196810, encodeId=2239219681076, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Wed Apr 03 17:05:30 CST 2024, time=2024-04-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2196466, encodeId=b04b2196466b9, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：在投中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKsHXJofxYo70D3uIMmicmpQlVNHz6fdFJWhllceA0wwUGibDBeWrjEXI0juVZ5gyVQnHciaEqryZ0cA/132, createdBy=59005107960, createdName=1234456789, createdTime=Mon Apr 01 15:37:07 CST 2024, time=2024-04-01, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2192712, encodeId=f5bf2192e125f, content=审稿速度:6.0 | 投稿命中率:5.0 偏重的研究方向：甲状腺肿瘤 经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Tue Mar 12 10:14:32 CST 2024, time=2024-03-12, status=1, ipAttribution=广西)]

2024-03-12 ms2000000185262432 来自广西

审稿速度:6.0 | 投稿命中率:5.0
偏重的研究方向：甲状腺肿瘤
经验分享：去年十一月投的稿件了，期间有一位审稿人接受，最近又变成了最原始的状态，什么消息也没有，打算催稿了

20 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务